RNA and RNA Derivatives: Light and Dark Sides in Cancer Immunotherapy-Reference-Cited by-全球学者库

RNA and RNA Derivatives: Light and Dark Sides in Cancer Immunotherapy

Published:2022-12-01 Issue:16-18 Volume:37 Page:1266-1290
ISSN:1523-0864
Container-title:Antioxidants & Redox Signaling
language:en
Short-container-title:Antioxidants & Redox Signaling

Author:

Deng Yuan¹,Xiao Min¹,Wan Arabella H.²³,Li Jiarui¹,Sun Lei¹,Liang Heng¹,Wang Qiao-Ping⁴,Yin Sheng¹,Bu Xianzhang¹,Wan Guohui¹^ORCID

Affiliation:

1. National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, National Engineering Research Center for New Drug and Druggability (Cultivation), Guangdong Province Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.

2. Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China.

3. Department of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.

4. School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Shenzhen, China.

Publisher

Mary Ann Liebert Inc

Subject

Plant Science,Forestry,Cell Biology,Clinical Biochemistry,Molecular Biology,Physiology,Biochemistry

Link

https://www.liebertpub.com/doi/pdf/10.1089/ars.2022.0035

Reference167 articles.

1. Analysis of copy number alterations reveals the lncRNA ALAL-1 as a regulator of lung cancer immune evasion

2. Functional screening identifies MCT4 as a key regulator of breast cancer cell metabolism and survival

3. Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

4. Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours

5. MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells